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a  b  s  t  r  a  c  t
Sanaria  Inc.  has  developed  methods  to manufacture,  purify  and cryopreserve  aseptic  Plasmodium  falcip-
arum  (Pf)  sporozoites  (SPZ),  and  is using  this  platform  technology  to develop  an injectable  PfSPZ-based
vaccine  that provides  high-grade,  durable  protection  against  infection  with  Pf malaria.  Several  candidate
vaccines  are  being  developed  and  tested,  including  PfSPZ  Vaccine,  in  which  the  PfSPZ  are  attenuated  by
irradiation,  PfSPZ-CVac,  in  which  fully  infectious  PfSPZ  are  attenuated  in  vivo  by concomitant  adminis-
tration  of an  anti-malarial  drug,  and  PfSPZ-GA1,  in  which  the  PfSPZ  are  attenuated  by gene  knockout.
Forty-three  research  groups  in 15 countries,  organized  as  the  International  PfSPZ  Consortium  (I-PfSPZ-
C),  are collaborating  to  advance  this  program  by  providing  intellectual,  clinical,  and ﬁnancial  support.
Fourteen  clinical  trials  of these  products  have  been  completed  in the USA,  Europe  and  Africa,  two  are
underway  and  at least  12 more  are  planned  for 2015–2016  in  the  US  (four  trials),  Germany  (2  trials),
Tanzania,  Kenya,  Mali,  Burkina  Faso,  Ghana  and  Equatorial  Guinea.  Sanaria  anticipates  application  to
license  a ﬁrst  generation  product  as  early  as  late  2017,  initially  to  protect  adults,  and  a year  later  to  pro-
tect  all  persons  >6  months  of age  for at least  six  months.  Improved  vaccine  candidates  will  be  advanced
as  needed  until  the  following  requirements  have  been  met:  long-term  protection  against  natural  trans-
mission,  excellent  safety  and  tolerability,  and  operational  feasibility  for population-wide  administration.
Here  we  describe  the  three  most  developed  whole  PfSPZ  vaccine  candidates,  associated  clinical  trials,
initial  plans  for  licensure  and  deployment,  and  long-term  objectives  for  a ﬁnal  product  suitable  for  mass
administration  to achieve  regional  malaria  elimination  and  eventual  global  eradication.
ublis©  2015  The  Authors.  P
. BackgroundThe Plasmodium sporozoite (SPZ), transmitted to the human
ost by female Anopheles mosquitoes, is an attractive vaccine
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candidate. If immune responses induced by such a vaccine could
kill the SPZ during its journey from the mosquito proboscis to the
liver or during development in the liver (pre-erythrocytic stages
of the parasite life cycle), there would be no blood stage infection
and no production of gametocytes. This would address an urgent
public health priority, namely protecting people in endemic areas
from clinical malaria, especially those susceptible to severe disease
such as infants and young children. A pre-erythrocytic stage
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Box 1: Targeting the SPZ.
Whole SPZ were one of the ﬁrst malaria immunogens tested
as a malaria vaccine, described by Sergent and Sergent in a
report published in 1910 by the Academy of Sciences, Paris,
on the avian parasite Plasmodium relictum [2]. In the early
1940s, Mulligan, Russell and Mohan at the Pasteur Institute
in Coonoor, India partially protected fowl against another bird
parasite, P. gallinaceum, by administering ﬁve intravenous
injections of a crude preparation of dried, ground thoraces
from infected mosquitoes (220 thoraces per fowl) [3,4]. Vacci-
nated animals and controls were challenged by the bites of two
infected Aëdes albopictus mosquitoes, and while all immu-
nized fowl developed asexual blood stage infections (thus
protection against infection was nil), prior SPZ vaccination
halved the parasite density in the blood, and reduced mortal-
ity from 55% to 30% or less. Similar results were obtained with
SPZ dissected from salivary glands and inactivated by a 30-min
exposure to ultraviolet light. The partial protection by killed
SPZ in the avian model was conﬁrmed in subsequent stud-
ies [5]. It was shown that protected fowl were still susceptible
to blood stage challenge, indicating that the partially effective
immune response induced by whole killed SPZ vaccination
targeted the pre-erythrocytic stages.
A signiﬁcant improvement in protection was reported by
Nussenzweig and colleagues in 1967 by using attenuated,
rather than killed SPZ, this time in a rodent model. X-irradiation
was used to damage P. berghei SPZ dissected from infected
Anopheles stephensi mosquitoes [6]. SPZ receiving this sub-
lethal irradiation remained metabolically active and motile,
could invade hepatocytes and round up (a morphological
change signifying the earliest stage of development in the
hepatocyte), but could not develop into hepatic trophozoites
or schizonts. When mice immunized by IV administration of
75,000 SPZ irradiated with 80–100 gray (Gy) were challenged
by IV injection of non-irradiated SPZ two weeks after immuniza-
tion, infection rates were 37% compared to 90% in controls,
indicating that more than half had sterile immunity against
infection. Those animals becoming infected despite vaccina-
tion showed delays in the prepatent period. Eleven protected
mice were re-challenged at 36 days, and most were again pro-
tected, indicating a degree of immune durability and also ruling
out non-speciﬁc protection mediated by the innate immune
system. The murine model thus established that attenuated,
metabolically active parasites could induce sterile immunity
to malaria.
The radiation-attenuated SPZ approach was rapidly translated
to humans in a series of studies in the early 1970s carried
out by Clyde and colleagues [7–11], and Rieckmann and col-
leagues [12–14] and to non-human primates [15]. A review of
these studies and subsequent work by the US military [16,17]
and the University of Maryland [18,19] by Hoffman et al. [16]
concluded that administration of more than 1000 bites from
irradiated, infected mosquitoes consistently protected >90%
(13/14) of recipients undergoing CHMI by mosquito bite within
10 weeks of immunization, and 5/6 volunteers were still pro-
tected on repeat CHMI up to 42 weeks later. Furthermore, 4
subjects underwent 7 CHMIs with heterologous strains of Pf,
and there was 100% protection. 150 Gy was established as a
sufﬁciently attenuating radiation dose to prevent blood stage
infection without killing the parasites.
This work provided proof-of-concept for high-grade protection
against parasitemia in humans by targeting the SPZ (and/or
the early liver stage parasites they become), and inspired
efforts to develop pre-erythrocytic stage malaria vaccines. It
was reasoned that if the antigenic components of whole SPZ
could be identiﬁed and suitably formulated as vaccines, it
should be possible for subunits to reproduce the high-gradeT.L. Richie et al. / Vac
accine would also beneﬁt travelers, obviating the difﬁculties of
rophylactic drug compliance and side effects. Ultimately, a highly
ffective pre-erythrocytic stage vaccine, serving as a vaccine to
nterrupt malaria transmission (VIMT), would be the ideal tool to
liminate malaria and contain the spread of malaria parasites from
eﬁned geographic regions, leading to global eradication [1].
.1. Targeting the sporozoite
Several approaches have been taken to induce protective immu-
ity against SPZ. Forty years ago injection of attenuated whole
PZ was shown to protect rodents against malaria infection, fol-
owed quickly by proof-of-concept that the same approach works
n humans (Box 1). However, at that time SPZ had to be adminis-
ered to humans by mosquito bite, limiting feasibility as a vaccine
pproach. The alternative, producing large numbers of infected
osquitoes, harvesting the SPZ, and purifying them from contam-
nating salivary gland antigens, also appeared to be difﬁcult if not
mpossible, especially as the puriﬁed sporozoites would have to
e aseptic for injection. All in all, immunization with whole sporo-
oites was felt to be “too crude and impractical to produce a vaccine
or wide application” [27].
.2. Whole sporozoites for parenteral injection
Sanaria Inc., a biotechnology company in Rockville, Maryland,
pent the last 10 years addressing the challenges of production,
uriﬁcation and cryopreservation, and now routinely manufac-
ures vials of highly puriﬁed, aseptic P. falciparum (Pf) SPZ that
re in compliance with regulatory standards for purity, potency,
afety and consistency [28]. 2155 doses of PfSPZ (doses as high as
.2 million PfSPZ) have now been administered to 824 adults by
he intradermal (ID), subcutaneous (SC), intramuscular (IM), intra-
enous (IV) or direct venous inoculation (DVI) routes, and have
hown excellent safety and tolerability. In blinded, randomized,
lacebo-controlled trials, the PfSPZ have not caused any detectable
ystemic reactogenicity (Sissoko et al., unpublished; Mordmüller
t al., unpublished) [29] or allergic responses, indicating that
fSPZ may  be suitably safe for mass administration campaigns for
alaria elimination.
Because Plasmodium is a eukaryotic organism, the PfSPZ need
o be cryopreserved and stored in liquid nitrogen vapor phase
LNVP) to maintain viability, like other cellular therapies or prod-
cts (mammalian sperm, eggs, embryos, cellular cancer vaccines),
s well as eleven veterinary vaccines including the Theileria parva
accine used in Africa. Indeed, LNVP storage may  prove to be advan-
ageous, enhancing delivery to remote areas since no electricity is
eeded to maintain the cold chain (compared to refrigerated vac-
ines), and the vaccine can remain stable for weeks to months in
 free-standing container. LN is widely available across Africa and
ther tropical areas, with infrastructure in place to support veteri-
ary vaccine applications, artiﬁcial insemination of cattle, oil and
ining applications, and the brewing industry. Distribution of the
accine in LNVP is feasible in malaria endemic countries using a
ub and spoke model, and projected costs are roughly equivalent
o those required for adding a new vaccine to current distribution
etworks for refrigerated (2–8 ◦C) vaccines [30].
PfSPZ, the core Sanaria product, are manufactured in accordance
ith Title 21 of the Code of Federal Regulations (21 CFR) and in
ccordance with International Conference on Harmonization (ICH)
uidelines. Manufacturing of PfSPZ products is performed follow-
ng current Good Manufacturing Practice (cGMP) guidelines where
rocesses are deﬁned and controlled to ensure consistency and
ompliance with speciﬁcations. PfSPZ products have excellent sta-
ility proﬁles even when stored for more than 4 years. Sanaria
aintains Biologics Master Files with the US FDA, and all clinical
protection induced by whole SPZ. The report in 1984 of the
identiﬁcation and cloning of the major surface protein of the
P. falciparum (Pf) SPZ, the circumsporozoite protein (CSP)
[20], galvanized this effort, and led to the clinical testing of
7454 T.L. Richie et al. / Vaccine 3
a series of recombinant and synthetic constructs [22,23], the
most successful being RTS,S, a recombinant protein contain-
ing a portion of PfCSP fused to hepatitis B surface antigen,
produced in yeast, assembled into virus-like particles, and
formulated in adjuvant. RTS,S has been extensively tested
in Africa, and the results of a large Phase 3 trial recently
reported [24]. In addition to RTS,S, several other subunit
approaches using pre-erythrocytic stage antigens are being
pursued, including gene-based approaches; some, like RTS,S,
have sterilely protected volunteers against CHMI [25,26]. While
these subunit approaches are promising, they present the
immune system with only a small number of pre-erythrocytic
immunogens, and have provided only modest protection. With
the development by Sanaria of technologies for the manufac-
ture and administration of whole SPZ, many  in the malaria
vaccine development ﬁeld have begun to direct their efforts
t
n
u
2
P
S
i
P
a
n
v
m
b
b
h
v
c
c
h
2
i
a
c
b
M
m
R
t
2
s
C
b
e
3
b
c
m
s
t
i
t
Barcelona the PfSPZ were administered by DVI, inserting the 25 G
needle of a 1 mL  syringe directly into a vein and rapidly injecting
the PfSPZ in a volume of 0.5 mL  (Fig. 1). This standard dose and DVI
administration were used by the Lambaréné Centre for Medical
Fig. 1. Direct venous inoculation (DVI) of PfSPZ [42]. Once the injection site isback toward this more empirical whole organism approach (see
Box 2).
rials are conducted with US FDA oversight under investigational
ew drug applications (IND), and with appropriate host nation reg-
latory oversight.
. Products
Sanaria’s ﬁrst PfSPZ products are based on the NF54 strain of
f, isolated in 1981 from a Dutch farmer living near Amsterdam’s
chiphol Airport and originating in Africa [31,32]. Pf NF54 strain
s chloroquine sensitive. More recently, Sanaria has manufactured
fSPZ derived from a clone of a Brazilian isolate, 7G8 [33], as well
s PfSPZ from a Cambodian clone, NF135.C10 [34].
Controlled human malaria infection (CHMI) and exposure to
atural transmission have been used to test the efﬁcacy of Sanaria’s
accine products. CHMI has been performed by mosquito bite, using
osquitoes infected with NF54, 3D7 (a clone of NF54) or 7G8, or
y the direct injection of infectious PfSPZ (NF54) manufactured
y Sanaria. When NF54 or 3D7 are used, the CHMI is considered
omologous, since the parasite is identical or highly similar to the
accine. When other strains are used to assess efﬁcacy, the CHMI is
onsidered heterologous, and a potentially better predictor of efﬁ-
acy under conditions of natural transmission, where mosquitoes
arbor heterogeneous populations of Pf.
.1. PfSPZ Vaccine
The ﬁrst PfSPZ product developed using Sanaria’s manufactur-
ng technology was Sanaria® PfSPZ Vaccine, which is composed of
septic, puriﬁed, live (metabolically active), radiation-attenuated,
ryopreserved PfSPZ. Several clinical trials of PfSPZ Vaccine have
een completed in the USA. In the ﬁrst trial, conducted at the Naval
edical Research Center (NMRC), the University of Maryland Balti-
ore, Center for Vaccine Development (UMB CVD), and the Walter
eed Army Institute of Research (WRAIR), the vaccine was adminis-
ered ID or SC, was poorly immunogenic and protected at best only
 of 16 volunteers at one dosage against CHMI [35]. A concurrent
tudy in non-human primates (NHP) at the NIH Vaccine Research
enter (VRC) administered the vaccine SC, as in the clinical trial, and
y direct venous inoculation (DVI), as done in the original rodent
xperiments (Box 1). DVI induced far superior immune responses:
.2% of CD8+ T cells in the livers of the three NHPs immunized
y DVI responded with IFN production to PfSPZ stimulation,
ompared with low to undetectable frequencies in SC-immunized
onkeys [35]. This ﬁnding provided the proof of concept for theecond trial, conducted at the VRC, where the vaccine was given IV
hrough an in-dwelling catheter. This trial escalated through ﬁve
ncreasing doses of the vaccine, administering four to six injections
o the volunteers over the course of 20–26 weeks. Sterile protection3 (2015) 7452–7461
in 6/6 (100%) subjects receiving the highest total dose (Table 1)
demonstrated that the PfSPZ were potent and provided the critical
proof-of-principle that the model of protection by mosquito bite
with radiation-attenuated SPZ (Box 1) could indeed be translated
into a human injectable product. There was a clear dose-threshold
effect, with the three lower doses showing limited, but dose-
related protection, and the highest dose conferring high-grade
sterile immunity (Table 1). There was a dose response for antibody
and cellular immune responses, and antibody responses to PfSPZ
were associated with protection. The most signiﬁcant association
was with antibodies to PfSPZ measured by the inhibition of
sporozoite invasion into hepatocytes (ISI) assay [36].
2.2. PfSPZ Challenge
Sanaria® PfSPZ Challenge is manufactured identically to PfSPZ
Vaccine except that the PfSPZ are not irradiated, and are therefore
fully infectious. CHMI with injectable PfSPZ can replace traditional
CHMI by the bite of mosquitoes to measure vaccine and drug
efﬁcacy, as well as to increase understanding of factors (genetic,
immune) that affect Pf infectivity. The optimal dose and route
for administering PfSPZ Challenge were worked out in a series of
eight clinical trials conducted from 2010 to 2014, with the ﬁrst
ﬁve testing ID and IM routes. These were conducted at Radboud
University Medical Center (RUMC), Nijmegen, the Netherlands
[37], the University of Oxford, Oxford, UK [38], the Ifakara Health
Institute (IHI), Bagamoyo, Tanzania [29], UMB  CVD [51], and
the Kenya Medical Research Institute (KEMRI), Nairobi, Kenya
[39,40]. The aim of these studies was  to administer a dose of PfSPZ
Challenge that reproduced the infectivity and prepatent period
of ﬁve PfSPZ-infected mosquitoes, namely 100% of volunteers
infected and a prepatent period by thick smear microscopy of <12
days. ID administration has achieved 100% infection rates, but not
the target prepatent period. IM administration of 7.5 × 104 PfSPZ
achieved both attributes [41]. IV inoculation using an in-dwelling
intravenous catheter was  ﬁrst tested at the University of Tübingen,
Germany, and achieved 100% infection rate after administering
only 3.2 × 103 PfSPZ [42]. The geometric mean (GM) prepatent
period was  11.2 days (range 10.5–12.5 days). These results were
then reproduced at the Barcelona Centre for International Health
(CRESIB), Spain [41,42], establishing 3.2 × 103 PfSPZ of PfSPZ
Challenge as the new gold standard for “mosquito-free” CHMI. Inprepped with an antiseptic such as 70% isopropyl alcohol, needle insertion, loos-
ening the tourniquet and vaccine injection take only about 10–15 s. Note the small
size of the needle (25 gauge) and syringe (1 mL), and blood ﬂashback conﬁrming
successful puncture of, in this case, the median cubital or cephalic vein. Veins in the
back of the hand or side of the wrist may  also be used. Photograph by B. Mordmüller.
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Table  1
Summary of protective efﬁcacy and antibody responses in volunteers immunized in the VRC 312 clinical trial with PfSPZ Vaccine [36].
Dosage regimen Anti-PfCSP Antibodies (OD 1.0)a Number of volunteers Protective efﬁcacy
Dose (PfSPZ × 105) Number of doses Maximum total dose (PfSPZ × 105) Challenged Protected
0.075 4 or 6 0.45 13 6 0 0%
0.3  4 or 6 1.8 324 11 1 9%
1.35 4 5.4 3454 9 6 60%b
1.35 5 6.75 6716 6 6 100%
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pa Anti-PfCSP antibody level 2 weeks after the last dose and before CHMI by ELISA
as  1.0).
b 5/6 controls developed parasitemia.
esearch in Gabon to study the effect of naturally acquired immu-
ity and sickle cell trait on the growth rate of Pf in vivo (Lell et al.,
npublished). These studies were performed using different PfSPZ
hallenge lots, some of which were manufactured years apart. In
ummary, these studies of PfSPZ Challenge demonstrated that the
uriﬁed, cryopreserved PfSPZ produced by Sanaria were potent
infectious) and stable, and that IV and DVI routes were the most
fﬁcient means of administration.
Having established a standard route and dose, injections of
.2 × 103 PfSPZ of PfSPZ Challenge, administered by DVI, have now
een used successfully in seven CHMIs in Tanzania and Germany
o test the efﬁcacy of PfSPZ Vaccine and PfSPZ-CVac respectively,
nfecting all control volunteers (n = 43) (Mordmüller et al., unpub-
ished; Shekalaghe et al., unpublished). CHMI by PfSPZ Challenge
educes costs and streamlines the logistics compared with CHMI
y mosquito bite. It also allows repeated CHMIs and adaptive clin-
cal trial designs, since the timing of CHMI is independent of the
omplex process needed to produce a batch of infected mosquitoes.
ince each inoculation is identical, PfSPZ Challenge also standard-
zes the dose of infectious PfSPZ, which cannot be done with CHMI
y mosquito bite.
.3. PfSPZ-CVac
In a seminal study of chemoprophylaxis with SPZ (CPS)
onducted at RUMC in Nijmegen [43], 3 × 12–15 bites from
on-irradiated Anopheles stephensi mosquitoes harboring PfSPZ
dministered to malaria-naïve adults concurrently taking chloro-
uine resulted in 100% sterile protection against CHMI (10/10
olunteers protected). The protection persisted for at least 28
onths in the majority of volunteers undergoing a second
HMI, with 4/6 sterilely protected and 2/6 showing prolonged
repatent periods [44]. The Sanaria team and collaborators rea-
oned that PfSPZ Challenge should be able to substitute for the
osquito bites, and accordingly, PfSPZ Challenge was tested as the
mmunogen in a CPS vaccine approach called Sanaria® PfSPZ-CVac
CVac = Chemoprophylaxis Vaccine).
The ﬁrst PfSPZ-CVac trial was conducted at RUMC; PfSPZ Chal-
enge was administered ID with chloroquine as the drug partner.
isappointingly, but in hindsight not unexpectedly, three or four ID
dministrations of 75,000 PfSPZ induced minimal immunogenicity
nd little or no protection [45]. Once the superiority of the IV route
as demonstrated for PfSPZ Vaccine in the VRC312 trial, however,
here was justiﬁcation for a second trial of PfSPZ-CVac, which was
onducted at the University of Tübingen. PfSPZ were administered
y DVI rather than ID, chloroquine was retained as the partner drug,
nd this time the outcome was dramatically reversed [Mordmüller
t al., unpublished]. The transformation from low- to high-grade
mmunogenicity and efﬁcacy mirrored the similar transformation
or PfSPZ Vaccine when the route of administration was  changed
rom ID or SC to IV. The ﬁnding that IV or DVI administration was
eeded to reveal the potency of PfSPZ for immunizing volunteers
arallels experience with PfSPZ Challenge for which the IV or DVIetric mean of the inverse of the serum dilution at which the optical density (OD)
route was  by far the most efﬁcient for infecting volunteers. Thus
for each objective – inducing protective immunity with PfSPZ Vac-
cine or the PfSPZ-CVac approach, or inducing infection with PfSPZ
Challenge – there was  a multifold difference in potency between
the IV/DVI routes of administration and the more traditional ID, SC
and IM routes.
2.4. Comparative potency of PfSPZ Vaccine and PfSPZ-CVac
Our cumulative experience using PfSPZ Vaccine shows that it
requires several hundred thousand PfSPZ to induce high-grade
protection, while the same or better can be achieved using the
PfSPZ-CVac approach using a fraction of the dose. This parallels ear-
lier experience using mosquito bite immunization: with CPS, it took
exposure to ∼45 PfSPZ-infected mosquitoes to achieve durable,
high-level protective efﬁcacy. In contrast, it required exposure to
the bites of at least 1000 mosquitoes carrying radiation-attenuated
PfSPZ to consistently achieve high-level protection (Box 1). The
likely reason for this is that radiation-attenuated PfSPZ invade
hepatocytes and begin the process of development, and although
they express ∼1000 proteins their replication arrests early in liver
stage development. In contrast, the infectious PfSPZ in PfSPZ-CVac
invade hepatocytes, but then replicate 10,000–40,000-fold and
express ∼4500 different proteins, including blood stage proteins.
Thus there are dramatically more parasites and antigens presented
to the immune system per PfSPZ injected with PfSPZ-CVac than
with PfSPZ Vaccine.
2.5. PfSPZ-GA1
Sanaria® PfSPZ-GA1 consists of puriﬁed, aseptic, cryopreserved
Pf sporozoites (NF54 strain) genetically attenuated by removal of
the b9 and slarp genes to halt development in the early liver stages
[46,47]. The parasite line was generated by the Leiden University
Medical Center (LUMC) and RUMC in collaboration with Sanaria.
Pfb9slarp parasites invade hepatocytes but are incapable of sus-
taining liver stage development, similar to radiation-attenuated
PfSPZ. The potential advantages of PfSPZ-GA1 are that (1) the PfSPZ
are homogenous and have a precisely characterized genetic basis
for attenuation; (2) manufacturing PfSPZ-GA1 cannot result in acci-
dental exposure of staff to infectious parasites, thereby simplifying
the approach to safety of operators and lowering costs. PfSPZ-GA1
also has the potential to induce more efﬁcient protection than the
radiation-attenuated PfSPZ Vaccine due to a different pattern of
developmental arrest and antigen expression.
2.6. Safety and tolerability
To date, 2155 doses of cryopreserved PfSPZ from Sanaria prod-
ucts have been administered to 824 adult volunteers in 17 clinical
trials via a variety of routes (Sanaria, unpublished). Several of these
trials included randomized, double-blind allocation to PfSPZ or nor-
mal  saline (NS) placebo, and data are available from three such
trials, involving 97 PfSPZ recipients and 68 placebo recipients in
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otal. The two groups were compared in each trial after unblind-
ng the adverse event data; there were no differences in adverse
vent proﬁles between volunteers receiving PfSPZ and placebo dur-
ng the ﬁrst seven days after injection [29] (Sissoko, Healy et al.,
npublished; Mordmüller et al., unpublished). Moreover, there
ave been no allergic reactions to PfSPZ, nor any serious adverse
vents attributed to PfSPZ. Experience includes 30 IV injections of
 × 105 PfSPZ and 36 IM injections of 2.2 × 106 PfSPZ (Lyke, Seder
t al., unpublished). The absence of clinically signiﬁcant side effects
inked to PfSPZ administration applies also to laboratory abnormal-
ties, including liver function tests.
DVI is rapid and efﬁcient (Fig. 1). If the veins in the arm are
uitable for obtaining blood via standard venipuncture, they are
uitable for administration of PfSPZ by DVI. The procedure involves
he insertion of a 25 G needle into the vein, a slight withdrawal
n the plunger to demonstrate blood ﬂashback, loosening of the
estricting tourniquet and immediate injection of 0.5 mL  of diluted
fSPZ (or placebo), typically taking 10–15 s. More than half (in some
rials >90%) of subjects have rated the injections as painless on a
our-point scale (painless, mild pain, moderate pain, severe pain).
VI may  cause slight bruising at the injection site if there is extrava-
ation of blood from the vein, but there are no persistent local signs
r symptoms such as tenderness, erythema or induration, since
he vaccine is dispersed on injection. ID and SC injections are also
ell tolerated, indicating that if any inoculum is deposited into the
urrounding tissues during DVI, it does not affect tolerability. The
accine contains no adjuvant or pro-inﬂammatory material.
The demonstrated safety of PfSPZ at doses up to 9 × 105 PfSPZ
y DVI has enabled plans for further dose escalation, in order to
aximize the degree and duration of sterile immunity, and this
ill be done for both PfSPZ Vaccine and PfSPZ-CVac. An interesting
spect of the latter approach when using chloroquine as the anti-
alarial is that 5.5–7 days after injection merozoites are released
nto the blood and are detectable by qPCR, providing a transient
ow-grade parasitemia that is rapidly cleared by chloroquine. The
inetics of transient parasitemia allow an estimate of the number
f infected hepatocytes, which can be used to correlate immunogen
ose (number of sporozoites infecting hepatocytes) with protective
fﬁcacy.
. Clinical development plan
.1. PfSPZ Vaccine
Springboarding off the two published trials of PfSPZ Vaccine
35,36], particularly following the high-grade protection in VRC
12 and ongoing studies, there are ﬁve new trials completed or
nderway of this product that constitute “Stage 1” of the PfSPZ
accine clinical development plan (CDP) (Fig. 2). Each of these tri-
ls was initiated by the primary performing institutions (Table 2),
hich also provided funding and developed protocols in close
artnership with Sanaria. These studies have reproduced the high-
rade efﬁcacy seen in VRC 312, demonstrated that PfSPZ Vaccine
nduces heterologous and durable (12 month) protection against
HMI and against naturally-transmitted malaria, and that a three-
ose regimen can be highly protective. We  have also learned
hat malaria-naïve individuals in the U.S. respond better to the
accine than malaria-exposed individuals in Africa after receiv-
ng an identical dose and regimen, exhibiting multifold higher
iters of antibodies to PfCSP by ELISA. This indicates that increased
oses of PfSPZ, and potentially interval changes between doses,
ill be required to achieve high-level immunogenicity and ster-
le protection in malaria-exposed individuals. This difference in
esponsiveness may  result from the immune modulation caused3 (2015) 7452–7461
by repeated malaria infections. The speciﬁc results from these trials
will be published by the investigators.
Stage 2 of the clinical development plan, launched in late-2015,
will address the following objectives:
(1) Demonstrate high-grade sterile protection in malaria-naïve
adults, including durable (≥6 month) protection against het-
erologous CHMI following a simpliﬁed (e.g. three dose)
regimen. These studies aim to ﬁnalize the regimen for licen-
sure to protect travelers, including military personnel, during
stays in malarious areas.
(2) Demonstrate high-grade sterile protection in malaria-exposed
African adults, including durable (≥6 month) protection against
naturally-transmitted malaria following a similarly simpliﬁed
regimen. These studies aim to deﬁne a regimen that can be
used in malaria elimination campaigns to halt infection and
transmission.
(3) Evaluate the tolerability, immunogenicity and efﬁcacy of trun-
cated regimens: 0, 1, and 4 weeks; 0 and 1 week; 0, 2, 4 and
6 days or even a single immunization. These studies aim to
improve the operational feasibility of using the vaccine for all
indications.
(4) Demonstrate safety, immunogenicity and protection in African
infants 5 months or older and in young children. These studies
aim to protect the most vulnerable age groups from malaria
and will optimize dose of vaccine with respect to age and body
weight. We  hypothesize that because African infants have had
limited exposure to malaria, vaccinations will result in better
protective responses than for African adults thereby providing
an effective vaccine for the most vulnerable populations.
(5) Demonstrate safety in the elderly and in HIV-infected individ-
uals. These studies aim to show that screening for diminished
health or immunodeﬁciency will not be required when
conducting mass administration campaigns. Since radiation-
attenuated parasites cannot replicate, they should prove safe
in all individuals, including the immunocompromised.
(6) Evaluate efﬁcacy against P. vivax by CHMI and natural trans-
mission. Pv and Pf share tens of thousands of minimal T cell
epitopes [48,49], and PfSPZ may  induce cross-protective cell
mediated immunity.
(7) Establish immunological correlates of infection; all immune
responses measured in these trials will be assessed as potential
correlates.
(8) Continue with operational research in preparation for phase
3 clinical trials and elimination campaigns with the licensed
vaccine.
There are seven funded trials that will address these objectives
in the USA, Germany, Tanzania, Mali, Burkina Faso, Kenya and Equa-
torial Guinea (Table 2), plus one additional trial of a new strain of
PfSPZ Challenge. A program for studying PfSPZ Vaccine in preg-
nancy is in the planning stages.
Stage 3 of the CDP will include expanded safety testing and large
scale CHMI trials in malaria-naïve adults using one or more het-
erologous parasites for CHMI, and will also include large-scale ﬁeld
efﬁcacy trials in malaria endemic areas including all age groups
older than six months. These studies are planned for 2016–18.
The studies in malaria-naïve adults will support the targeted sub-
mission of a biologics license application (BLA) in 2017-18 for a
traveler’s vaccine, and the studies in endemic areas will support an
additional indication for use in endemic areas subsequently. Opera-
tionally we intend to initially target infants, age 6–12 months, to
reduce morbidity and mortality, and mass administration projects
intended to achieve halting of transmission and elimination of
malaria will follow.
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SFig. 2. Clinical development plan for PfS
.2. PfSPZ-CVacThe CDP for PfSPZ-CVac parallels that of PfSPZ Vaccine with the
dded necessity of optimizing the administration, dose and reg-
men of the partner drug. Development is being prioritized and
ccelerated because of PfSPZ-CVac’s increased potency compared
able 2
ummary of Stage 1 and Stage 2 PfSPZ Vaccine clinical trials. The performing institutions
Stage 1
Country Protocol name Primary performing i
USA VRC 314 NIAID Vaccine Resear
Center for Vaccine De
Mali 14-I-N010 Malaria Research & T
NIAID Laboratory for 
Tanzania BSPZV1 Ifakara Health Institu
Swiss Tropical and Pu
USA  WRAIR 2080 Naval Medical Resear
Walter Reed Army In
Equatorial Guinea EGSPZV1 Equatorial Guinea Mi
IHI
Swiss TPH
Medical Care Develop
La  Paz Medical Cente
Stage 2
Country Primary performing institutions Objectives 
Germany University of Tübingen Condensed regimens
Tanzania IHI
Swiss TPH
Age de-escalation to 
Mali  MRTC
LMIV
Dose escalation and e
Burkina Faso Centre National de Recherche et de
Formation sur le Paludisme (CNRFP)
Dose escalation and e
UMB  CVD
USA NMRC Finalized regimen for
UMB  CVD
WRAIR
Equatorial Guinea Equatorial Guinea MOHSW Efﬁcacy in adults
Comparison with PfS
Age escalation to 65
Age de-escalation to 
Safety in HIV positive
Kenya  Kenya Medical Research Institute
(KEMRI)
Age de-escalation fro
US  Centers for Disease Control (CDC)
NIAID VRC
Safety and efﬁcacy inccine. Current activities fall into Stage 2.
to PfSPZ Vaccine. One clinical trial is ongoing (TÜCHMI-002 trial
at the University of Tübingen), one clinical trial has just started at
the U.S. National Institutes of Health (NIH) Clinical Center, and three
additional trials are planned for 2015–2016 (Table 3). These include
trials of condensed regimens (as few as 3 doses in 10 days) and
alternative drug partners (atovaquone/proguanil, azithromycin,
 are core members of the expanding International PfSPZ Consortium (see Table 4).
nstitutions ClinTrials.gov Identiﬁer
ch Center (VRC), University of Maryland Baltimore,
velopment (UMB CVD)
NCT02015091
raining Center (MRTC), University of Bamako NCT01988636
Malaria Immunology and Vaccinology (LMIV)
te (IHI) NCT02132299
blic Health Institute (Swiss TPH)
ch Center (NMRC) NCT02215707
stitute of Research (WRAIR)
nistry of Health and Social Welfare (MOHSW) NCT02418962
ment International (MCDI)
r, Malabo, EG
Efﬁcacy assessment
 in adults CHMI – PfSPZ Challenge
infants and efﬁcacy in adults CHMI – PfSPZ Challenge
fﬁcacy in adults CHMI – PfSPZ Challenge
+ Natural exposure
fﬁcacy in adults Natural exposure
 adult travelers CHMI – Mosquito bite
PZ-CVac
infants
 subjects
CHMI – PfSPZ Challenge
m 10 year olds to infants
 infants Natural exposure
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Table 3
Summary of current and planned PfSPZ-CVac clinical trials.
Country Primary performing institutions Objectives Efﬁcacy assessment
Germany University of Tübingen Condensed regimens CHMI – PfSPZ Challenge
(current) (ClinicalTrials.gov NCT02115516) Alternative drug partner – azithromycin
USA  NIAID Laboratory of Malaria Immunology and Vaccinology
(LMIV)
Alternative drug partner – pyrimethamine CHMI – PfSPZ Challenge
(current) (ClinicalTrials.gov NCT02511054)
USA NIAID Division of Microbiology and Infectious Diseases (DMID) Dose escalation, condensed regimen CHMI – PfSPZ Challenge
Group Health Research Institute
Seattle BioMed
Ghana Kintampo Health Research Centre Dose escalation CHMI – PfSPZ Challenge
US  Navy
Germany University of Tübingen Alternative drug partners – atovaquone/proguanil CHMI – PfSPZ Challenge
Table 4
Members of the International PfSPZ Consortium. Partners and funding organizations are listed by country and do not necessarily match left to right.
Location Collaborative and funding partners Funding organizations
USA Naval Medical Research Center (NMRC), Department of Defense (DoD) Military Infectious Disease Research Program (MIDRP)
Walter Reed Army Institute of Research (WRAIR), DoD US Navy Advanced Medical Development Program
NIAID  Vaccine Research Center (VRC)a US Army Medical Materiel Development Activity (USAMMDA)
NIAID  Laboratory of Malaria Immunology and Vaccinology (LMIV)a NIAID Division of Microbiology and Infectious Diseases (DMID)
University of Maryland Baltimore, Center for Vaccine Development (UMB
CVD)
PATH Malaria Vaccine Initiative (MVI) (funded by Bill &
Melinda Gates Foundation) (BMGF)
Centers for Disease Control and Prevention (CDC)a Marathon Oil Corporation
Medical Care Development International (MCDI) Noble Energy
Atlantic Methanol Production Company (AMPCO)
Institute for OneWorld Health (funded by BMGF)
Europe  European Vaccine Initiative
Switzerland Swiss Tropical and Public Health Institute (Swiss TPH)a Swiss State Secretariat for Education, Research and Innovation
Germany University of Tübingena German Centre for Infection Research
The  Netherlands Radboud University Medical Center (RUMC), Top Institute Pharma
Leiden University Medical Center
Spain ISGlobal, Barcelona Centre for International Health Research (CRESIB)a CRESIB, Spanish Government
UK  Jenner Institute, Oxford Universitya,b The Wellcome Trust
Africa
Tanzania Ifakara Health Institute (IHI) Tanzania Commission on Science and Technology (COSTECH)
Equatorial Guinea Ministry of Health and Social Welfare Government of Equatorial Guinea
Equatorial Guinea LNG
Kenya Kenya Medical Research Institute (KEMRI)
Wellcome Trust Laboratories
Centre for Research in Therapeutic Sciences (CREATES)
Gabon Centre de Recherches Médicales de Lambaréné, Albert Schweitzer Hospital
Mozambique Manhic¸a Health Research Center (CISM)
Ghana Kintampo Health Research Center Ghana Ministry of Health
Mali Malaria Research and Training Center, University of Bamako (MRTC)
Burkina Faso Centre National de Recherche et de Formation sur le Paludisme (CNRFP)
Asia
Indonesia Eijkman-Oxford Clinical Research Unit (EOCRU), Jakarta
p
a
i
P
a
a
d
i
o
a
p
3
f
b
ca Invested institutional funds in clinical trials of PfSPZ-based products.
b Only involved with PfSPZ Challenge.
yrimethamine). Close attention is being paid to safety consider-
tions, since the PfSPZ-CVac approach includes injecting healthy
ndividuals with a human pathogen, notwithstanding the fact that
fSPZ Challenge (NF54) is highly sensitive to chloroquine and other
ntimalarials. Any regimen will require ingestion and retention of
 protective drug before the PfSPZ are administered. This will be
one under direct observation. The challenge during development
s to demonstrate that vaccination with PfSPZ-CVac is as safe as any
ther approach to vaccination. PfSPZ-CVac may  be most appropri-
te for use in elimination campaigns in endemic areas, where the
opulation is already exposed to natural malaria transmission.
.3. PfSPZ-GA1Clinical lots of PfSPZ-GA1 have been manufactured. A proposal
or the ﬁrst trial has been submitted for funding. The ﬁrst step will
e to establish adequate attenuation and to compare protective efﬁ-
acy with PfSPZ Vaccine. A vaccine based on genetically attenuatedPf designed to arrest development late in the liver stage or imme-
diately after release of parasites into the blood is also being actively
pursued, as such parasites will mimic  PfSPZ-CVac without the need
for administering anti-malarial drugs.
3.4. International SPZ Consortium
A key aspect of the CDPs for PfSPZ Vaccine, PfSPZ-CVac and
PfSPZ-GA1 is their reliance on an informed and proactive consor-
tium of research and funding institutions that together constitute
the International PfSPZ Consortium (I-PfSPZ-C) (Table 4). Mem-
bers meet periodically to share and critique data, and to discuss
plans. The most recent meetings were held 11-12 March 2015,
9 September 2015 and 29-30 October 2015 in Tübingen, Basel
and Philadelphia, respectively (Box 2). The enthusiasm and aggres-
sive research strategies of the I-PfSPZ-C have propelled innovative
approaches and greatly accelerated the development and testing
of PfSPZ-based products. Sanaria acts as sponsor for nearly all the
T.L. Richie et al. / Vaccine 3
Box 2: The International PfSPZ Consortium.
The International PfSPZ Consortium (I-PfSPZ-C) has evolved
to integrate the planning and governance of development
among the organizations collaborating to take PfSPZ Vaccine
and PfSPZ-CVac through to licensure. The I-PfSPZ-C has an
inclusive structure in which all individuals, groups, institutions
and funding organizations involved in studies with Sanaria’s
PfSPZ-based products participate in the planning of trials, and
reviewing data on safety, immunogenicity and protective efﬁ-
cacy of PfSPZ vaccines. They also contribute to the efforts to
raise funds to support the program. The I-PfSPZ-C has met
two to three times per year since November 2011, including
sessions organized in association with the annual meeting
of the American Society of Tropical Medicine and Hygiene
(ASTMH). The ﬁrst meeting of 2015 was held in March at the
University of Tübingen, Germany, and was attended by 81
individuals from 35 different institutions based in 14 different
countries in North America, Europe and Africa. More recently,
a meeting was held in October in association with the annual
meeting of the ASTMH in Philadelphia, and was attended by
106 individuals from 43 different institutions based in 16 differ-
ent countries. In addition to clinical investigators, participants
included representatives from African governments, policy
agencies, regulatory authorities and funding agencies.
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Yingda Wen, Bing Jiang, Maria Orozco, Rui Xu, James Overby, Steve
Matheny, Yeab Getachew, Enni Fomumbod, Mary King, Michellerials, which are conducted under US FDA oversight, as well as the
versight of regulatory authorities in the countries outside the US
here the trials are conducted. Sanaria also serves as lead organizer
or the I-PfSPZ-C and as a repository for information. Of particu-
ar importance is the dissemination of clinical data among sites, to
rovide alerts in case of adverse events, and to inform all partners
egarding outcomes which may  impact the design and manage-
ent of other trials. In the case of the meeting in Tübingen, results
f ﬁve clinical trials were reported to members long before publi-
ation in a scientiﬁc journal.
.5. Malaria elimination campaigns
A remarkable aspect of the PfSPZ development story has been
he ﬁnancial support by African partner countries, ﬁrst Tanzania,
hen Equatorial Guinea and, most recently, Ghana; this is an impor-
ant milestone in malaria vaccine development. A striking example
s occurring in Equatorial Guinea, which will support four trials
f PfSPZ Vaccine and associated operational research in Equatorial
uinea and Tanzania to optimize vaccine administration for later
se in malaria elimination campaigns. The Equatorial Guinea Gov-
rnment, Marathon Oil Corporation, Noble Energy, AMPCO, Medical
are Development International (MCDI) and Sanaria have part-
ered to conduct the four trials and are aiming to conduct a malaria
limination campaign after a PfSPZ-based vaccine is licensed for
his indication. The collaboration in Equatorial Guinea involves
ot only Equatorial Guinea Ministry of Health and Social Welfare
nd Sanaria investigators, but also a team from the Ifakara Health
nstitute in Bagamoyo, Tanzania, and collaborators from the Swiss
ropical and Public Health Institute, MCDI, and La Paz Medical Cen-
er. The ﬁrst phase of the demonstration will target elimination
f malaria from Bioko Island. The population of >250,000 endure
ngoing malaria transmission and signiﬁcant malaria-related mor-
idity and mortality despite a well-funded and executed malaria
ontrol program [50]. Plans for this campaign will be developed
uring the coming years, anticipating launch of the campaign
mmediately after licensure.3 (2015) 7452–7461 7459
4. Conclusions
With the development of PfSPZ-based products for parenteral
injection, the ﬁeld of malaria vaccines is returning to principles
of highly protective immunization ﬁrst established in birds in the
early 1900s, in mice in the 1960s and in humans in the 1970s (Box
1). The focus has been to reproduce the same durable protective
immunity using an injectable product that is safe for human use.
This approach, unencumbered by a priori restrictions on vaccine
design, has led to rapid progress, and should translate into a more
thorough understanding of the immunological mechanisms under-
lying protection. Moreover, the whole organism approach mirrors
that of many other live, attenuated vaccine products, nearly all of
which are highly protective.
The fact remains, however, that there are no vaccines licensed
to protect humans against parasites, which are far more complex
than viral or bacterial pathogens. It is therefore to be expected
that numerous innovations have been required, and these have
included novel manufacturing process steps for the production of
highly PfSPZ-infected, aseptic mosquitoes and purifying and cry-
opreserving the PfSPZ. On the clinical side, it has been necessary
to develop new immunization regimens, and to develop DVI  as a
method for efﬁcient PfSPZ administration. Further process reﬁne-
ments are anticipated in the coming years after licensure of the ﬁrst
generation PfSPZ vaccine(s), and these include in vitro development
of PfSPZ from sexual stage parasites. Although the worldwide need
for a malaria vaccine can be met  using current methods for manu-
facture, such innovations will simplify scale-up and reduce the cost
of goods.
The rapid progress achieved by the I-PfSPZ-C would not have
been possible without the open-minded and creative approaches
adopted by Sanaria and its collaborators. Members of the I-PfSPZ-
C have provided leadership in key developments including DVI
administration, condensed immunization regimens, and novel
vaccine concepts such as PfSPZ-CVac. Remarkably, our clinical
experience has demonstrated excellent safety and tolerability,
regardless of route of administration. This allows for the testing
of higher doses, which appear needed to achieve our objectives in
those with prior malaria exposure. As new technologies for man-
ufacturing, formulation, cryopreservation and administration are
developed, and as indicated by the results of ongoing clinical test-
ing, optimized vaccine candidates and immunization regimens will
be advanced under appropriate regulatory guidance. The long-term
goal is durable, cross-strain, sterile immunity in >90% of vaccine
recipients with the lowest numbers of PfSPZ in the least num-
bers of doses in the shortest period of time. The target product
must also demonstrate operational, safety and tolerability char-
acteristics suitable for use in mass administration campaigns. The
I-PfSPZ-C is working toward these long-term objectives, aiming for
a PfSPZ vaccine to be the cornerstone for malaria elimination and
eradication.
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